{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-24-002672","form_type":"8-K","ticker":"ANIK","cik":"0000898437","company_name":"Anika Therapeutics, Inc.","filed_at":"2024-05-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:22.378993+00:00","generated_at":"2026-06-02T15:00:28.405160+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Anika Therapeutics Q1 revenue up 7% to $40.5M; narrows net loss; reaffirms FY2024 guidance","bullets":["Q1 revenue $40.5M (+7% YoY); net loss narrowed to $4.5M from $10.4M; adjusted net income $1.2M ($0.09/dil share).","Adjusted EBITDA improved to $2.5M from ($1.2M) in Q1 2023; FY2024 adj EBITDA guidance $25-30M (midpoint up >75%).","Cost reduction initiatives completed, achieving $10M annualized savings; severance costs $0.8M in Q1.","Business highlights: extended Canadian distribution deal through 2030; >10,000 X-Twist anchors sold; Integrity Implant >200 cases."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-24-002672","json":"https://secwatch.observer/filing/0001171843-24-002672.json","markdown":"https://secwatch.observer/filing/0001171843-24-002672.md","text":"https://secwatch.observer/filing/0001171843-24-002672.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/898437/000117184324002672/0001171843-24-002672-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/898437/000117184324002672/f8k_050824.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T15:00:28.405160+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"f11467729b54dc68eddd2d314cefb11622b60720","claim":"Anika Therapeutics, Inc. reported first quarter ended March 31, 2024 results: revenue $40.5 million, net income $(4.5) million, or ($0.31) per share, EPS $0.09 per diluted share. Guidance reaffirmed.","evidence_excerpt":"orthopedics, today reported financial results for its first quarter ended March 31, 2024. First Quarter 2024 Financial Summary Revenue in the first quarter of 2024 was $40.5 million, up 7% compared to $37.9 million in the first quarter of 2023. OA Pain Management revenue of $24.3 million, up 7% Joint Preservation and Restoration revenue of $13.8 million, up","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/898437/000117184324002672/0001171843-24-002672-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2024"},{"label":"Revenue","value":"$40.5 million"},{"label":"Net income","value":"$(4.5) million, or ($0.31) per share"},{"label":"EPS","value":"$0.09 per diluted share"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}